FibroBiologics shows fibroblast spheroids reduce burn wound inflammation and scarring in preclinical study.

FibroBiologics announced preclinical data indicating that topical treatment with human dermal fibroblast spheroids can actively reprogram burn wounds by reducing inflammation, reshaping immune response, and lowering scar-forming activity within eight days. The treatment led to visibly less inflamed wounds and decreased expression of genes linked to scarring. These findings suggest potential for improved burn wound healing with less permanent damage, supporting FibroBiologics' expansion into burn care therapeutics. The company plans to build on this data to advance its wound care platform.